HVDs/HVDPs = safe drugs [Off Topic]

posted by varun9461 – India, 2019-02-22 12:23  – Posting: # 19966
Views: 1,890

» Coming back to clopidogrel: Its high variability is mainly caused by both presystemic and first-pass meta­bolism. The EMA in its Q&A-document do not recommend reference-scaling based on unclear clinical implications. Don’t know what USFDA’s current thinking is. The product-specific guidance is quite old (08/2008) and was issued before RSABE first appeared as an option (04/2010). The FDA generally does not require a clinical justification (contrary to the EMA) and allows scaling for both AUC and Cmax.

Question: wrt to EMA Q&A about clopidogrel not allowing widening on CMAX, can we plan full replicate BE study with BE Limit of 80.00-125.00% or two way cross over BE study needs to be performed?

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer (see also this post #5). Standard quotes restored (see in the same post #8). Please follow the Forum’s Policy[Helmut]

Complete thread:

 Admin contact
20,103 posts in 4,243 threads, 1,383 registered users;
online 10 (1 registered, 9 guests [including 6 identified bots]).
Forum time (Europe/Vienna): 09:51 CET

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz